Business
Combining forces to bring innovative combination therapies to Patients
Business Strategy
- MINC technology platform creates drugs for “breakthrough” designation
- Collaborations with top global KOLs
- Out-license drug candidates after Phase 1 to big pharma for late-stage clinical trials and commercialization.
- Revenue streams: mainly front and milestone payments and royalties. For these “breakthrough” drug candidates, the out-licensing values are typically USD $80-150 million front payments and USD $800-1200 million total milestone payments plus double-digit royalties.